Exclusive: U.S. approval of Merck cancer immunotherapy expected soon

August 25, 2014 11:06 AM

6 0

Exclusive: U.S. approval of Merck cancer immunotherapy expected soon

LOS ANGELES (Reuters) - U.S. regulators are likely to approve Merck & Co's highly anticipated immuno-oncology drug, pembrolizumab, as a treatment for melanoma well ahead of a late October deadline, according to three sources familiar with the situation.

If approved by the Food and Drug Administration, the drug would be the first in a promising new class designed to help the body's own immune system fend off cancer by blocking a protein known as Programmed Death receptor (PD-1), or a related target known as PD-L1, used by tumors to evade disease-fig...

Read more

To category page

Loading...